A phase 2B, randomised, multicenter, dose-ranging study assessing the safety and efficacy of PD 0348292 [eribaxaban] in the prevention of venous thromboembolic events in subjects undergoing an elective, unilateral total knee replacement

Trial Profile

A phase 2B, randomised, multicenter, dose-ranging study assessing the safety and efficacy of PD 0348292 [eribaxaban] in the prevention of venous thromboembolic events in subjects undergoing an elective, unilateral total knee replacement

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Eribaxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Oct 2007 Status changed from recruiting to completed.
    • 17 Jan 2007 New centres added.
    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top